RECRUITING

IMPACT Trial: Intervention to iMProve AdherenCe Equitably

Description

To determine the efficacy of a multicomponent adherence intervention among participants with early-stage breast cancer on endocrine therapy and at least one oral cardiovascular disease (CVD) medication on adherence to endocrine therapy and to CVD medication at 24 weeks assessed by self-report using the Domains of Subjective Extent (DOSE)-Nonadherence questionnaire and also by pharmacy fill data assessed in the electronic health record (EHR).

Conditions

Study Overview

Study Details

Study overview

To determine the efficacy of a multicomponent adherence intervention among participants with early-stage breast cancer on endocrine therapy and at least one oral cardiovascular disease (CVD) medication on adherence to endocrine therapy and to CVD medication at 24 weeks assessed by self-report using the Domains of Subjective Extent (DOSE)-Nonadherence questionnaire and also by pharmacy fill data assessed in the electronic health record (EHR).

IMPACT Trial: Intervention to iMProve AdherenCe Equitably

IMPACT Trial: Intervention to iMProve AdherenCe Equitably

Condition
Breast Cancer
Intervention / Treatment

-

Contacts and Locations

New York

Columbia University Medical Center, New York, New York, United States, 10032

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Women or men age \>18 years
  • * Diagnosed with stage I-III breast cancer prescribed endocrine therapy
  • * Within 3-years of the end of early active treatment (e.g., surgery, chemotherapy not including human epidermal growth factor receptor 2 (HER2)-directed therapy, radiation)
  • * Patients must be prescribed at least 1 antihypertensive or statin medication for CVD prevention
  • * Self-report of at least some nonadherence ET or CVD medication on DOSE-Nonadherence Extent of Nonadherence questionnaire
  • * Evidence of breast cancer recurrence
  • * Non-English or Non-Spanish speaking
  • * Not cognitively able to complete study requirements
  • * Do not follow with either a primary care provider or cardiologist within the New York Presbyterian Health system's Epic EHR
  • * Inability to provide informed consent

Ages Eligible for Study

18 Years to 99 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Columbia University,

Dawn Hershman, MD, PRINCIPAL_INVESTIGATOR, Columbia University

Study Record Dates

2027-03-31